

Certificate of Mailing


Date of Deposit: January 28, 2004

Label Number: EV 364162565 US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "**Express Mail Post Office to Addressee**" with sufficient postage on the date indicated above and is addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De La Cruz

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Larsen et al.	Art Unit:	Not Yet Assigned
Serial No.:	Not Yet Assigned	Examiner:	Not Yet Assigned
Filed:	January 28, 2004	Customer No.:	21559
Title:	RECEPTOR BINDING CONJUGATES		

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Under 35 U.S.C. § 120, this application relies on the earlier filing date of application serial number 09/731,301, which was filed on December 5, 2000. The following references were submitted to and/or cited by the Office in the prior application and, therefore, copies of these references are not provided for this application:

U.S. Patents

4,336,185	Jun. 22, 1982	Niswender
5,547,668	Aug. 20, 1996	Kranz et al.

U.S. Patents

6,077,499 Jun. 20, 2000 Griffiths et al.

PCT Publications

0 282 057 A2 Sept. 14, 1988 Europe

Other Publications

Bruland et al., "Expression and Characteristics of a Novel Human Osteosarcoma-Associated Cell Surface Antigen," *Cancer Res.*, 48:5302-5309 (1988).

Bruland et al., "New Monoclonal Antibodies Specific for Human Sarcomas," *Int. J. Cancer*, 38:27-31 (1986).

Bruland, "Cancer Therapy with Radiolabeled Antibodies. An Overview," *Acta Oncol.*, 34:1085-1094 (1995).

Campbell et al., "Folate-binding Protein Is a Marker for Ovarian Cancer," *Cancer Res.*, 51:5329-5338 (1991).

Fraker et al., "Protein And Cell Membrane Iodinations with a Sparingly Soluble Chloroamide, 1,3,4,6-Tetrachloro-3a,6a-Diphenylglycoluril," *Biochem. Biophys. Res. Comm.*, 80:849-857 (1978).

Larsen et al., "Inactivation of Human Osteosarcoma Cells *In Vitro* by ²¹¹At-TP-3 Monoclonal Antibody: Comparison with Astatine-211-Labeled Bovine Serum Albumin, Free Astatine-211 and External-Beam X Rays," *Radiat. Res.*, 139:178-184 (1994).

Larsen et al., "Preparation and Quality Control of ²¹¹At-Labelled and ¹²⁵I-Labelled Monoclonal Antibodies. Biodistribution in Mice Carrying Human Osteosarcoma Xenografts," *J. Labelled Compds. Radiopharmaceuticals*, 34:773-785 (1994).

Larsen et al., "α-Particle Radiotherapy with ²¹¹At-Labeled Monodisperse Polymer Particles, ²¹¹At-Labeled IgG Proteins, and Free ²¹¹At in a Murine Intraperitoneal Tumor Model," *Gynecol. Oncol.*, 57:9-15 (1995).

Mathias et al., "Indium-111-DTPA-Folate as a Potential Folate-Receptor-Targeted Radiopharmaceutical," *J. Nucl. Med.*, 39:1579-1585 (1998).


Reddy et al., "Folate-Mediated Targeting of Therapeutic and Imaging Agents to Cancers," *Critical Reviews in Therapeutic Drug Carrier Systems*, 15:587-627 (1998).

Shinoda et al., "In Vivo Fate of Folate-BSA in Non-Tumor- and Tumor-Bearing Mice," *J. Pharm. Sci.*, 87:1521-1526 (1998).

Trippett et al., "Therapeutic Strategies Targeting Proteins that Regulate Folate and Reduced Folate Transport," *J. Chemotherapy*, 11:3-10 (1999).

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,
Date: Jan. 28, 2004 

Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50147/003002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))				Serial No.	Not Yet Assigned	
				Applicant	Larsen et al.	
				Filing Date	January 28, 2004	
				Group	Not Yet Assigned	
				IDS Filed	January 28, 2004	
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	4,336,185	Jun. 22, 1982	Niswender			
	5,547,668	Aug. 20, 1996	Kranz et al.			
	5,698,178	Dec. 16, 1997	Goldenberg			
	6,077,499	Jun. 2000	Griffiths et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	0 282 057 A2	Sept. 14, 1988	Europe			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Bruland et al., "Expression and Characteristics of a Novel Human Osteosarcoma-Associated Cell Surface Antigen," <i>Cancer Res.</i> , 48:5302-5309 (1988).					
	Bruland et al., "New Monoclonal Antibodies Specific for Human Sarcomas," <i>Int. J. Cancer</i> , 38:27-31 (1986).					
	Bruland, "Cancer Therapy with Radiolabeled Antibodies. An Overview," <i>Acta Oncol.</i> , 34:1085-1094 (1995).					
	Campbell et al., "Folate-binding Protein Is a Marker for Ovarian Cancer," <i>Cancer Res.</i> , 51:5329-5338 (1991).					
	Fraker et al., "Protein And Cell Membrane Iodinations with a Sparingly Soluble Chloroamide, 1,3,4,6-Tetrachloro-3a,6a-Diphenylglycoluril," <i>Biochem. Biophys. Res. Comm.</i> , 80:849-857 (1978).					
	Larsen et al., "Inactivation of Human Osteosarcoma Cells <i>In Vitro</i> by ²¹¹ At-TP-3 Monoclonal Antibody: Comparison with Astatine-211-Labeled Bovine Serum Albumin, Free Astatine-211 and External-Beam X Rays," <i>Radiat. Res.</i> , 139:178-184 (1994).					
	Larsen et al., "Preparation and Quality Control of ²¹¹ At-Labelled and ¹²⁵ I-Labelled Monoclonal Antibodies. Biodistribution in Mice Carrying Human Osteosarcoma Xenografts," <i>J. Labelled Compds. Radiopharmaceuticals</i> , 34:773-785 (1994).					
	Larsen et al., "α-Particle Radiotherapy with ²¹¹ At-Labeled Monodisperse Polymer Particles, ²¹¹ At-Labeled IgG Proteins, and Free ²¹¹ At in a Murine Intraperitoneal Tumor Model," <i>Gynecol. Oncol.</i> , 57:9-15 (1995).					
	Mathias et al., "Indium-111-DTPA-Folate as a Potential Folate-Receptor-Targeted Radiopharmaceutical," <i>J. Nucl. Med.</i> , 39:1579-1585 (1998).					
	Reddy et al., "Folate-Mediated Targeting of Therapeutic and Imaging Agents to Cancers," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 15:587-627 (1998).					
	Shinoda et al., "In Vivo Fate of Folate-BSA in Non-Tumor- and Tumor-Bearing Mice," <i>J. Pharm. Sci.</i> , 87:1521-1526 (1998).					
	Trippett et al., "Therapeutic Strategies Targeting Proteins that Regulate Folate and Reduced Folate Transport," <i>J. Chemotherapy</i> , 11:3-10 (1999).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						